Qsemble Capital Management, LP Halozyme Therapeutics, Inc. Transaction History
Qsemble Capital Management, LP
- $751 Billion
- Q4 2024
A detailed history of Qsemble Capital Management, LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Qsemble Capital Management, LP holds 4,396 shares of HALO stock, worth $252,022. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,396Holding current value
$252,022% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
541Shares Held
123MCall Options Held
395KPut Options Held
172K-
Black Rock Inc. New York, NY17.6MShares$1.01 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$761 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$380 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$233 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$195 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.99B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...